Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial

Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial

Introduction: Sequential therapy with vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) is effective in some patients with metastatic renal cell carcinoma (mRCC) progressed from or were intolerant to a prior TKIs. Anlotinib is a multi-kinase inhibitor targeting VEGF...

Full description

Bibliographic Details
Main Authors:	Jianhui Ma, Yan Song, Jianzhong Shou, Yuxian Bai, Hanzhong Li, Xiaodong Xie, Hong Luo, Xiubao Ren, Jiyan Liu, Dingwei Ye, Xianzhong Bai, Cheng Fu, Shukui Qin, Jinwan Wang, Ai-Ping Zhou
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2020-05-01
Series:	Frontiers in Oncology
Subjects:	anlotinib metastatic renal cell carcinoma tyrosine kinase inhibitor second-line FGFR
Online Access:	https://www.frontiersin.org/article/10.3389/fonc.2020.00664/full

Similar Items

Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double‐blind randomized phase 2 trial
by: Jing Huang, et al.
Published: (2021-03-01)

Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development
by: Guoshuang Shen, et al.
Published: (2018-09-01)

Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma
by: Wang H, et al.
Published: (2020-02-01)

Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation
by: Jian-zhou Cao, et al.
Published: (2021-05-01)

Anlotinib Suppresses Colorectal Cancer Proliferation and Angiogenesis via Inhibition of AKT/ERK Signaling Cascade
by: Yang Q, et al.
Published: (2020-06-01)

The Activity and Safety of Anlotinib for Patients with Extremity Desmoid Fibromatosis: A Retrospective Study in a Single Institution
by: Zheng C, et al.
Published: (2020-09-01)

Case Report: Anlotinib Reverses Nivolumab Resistance in Advanced Primary Pulmonary Lymphoepithelioma-Like Carcinoma With FGFR3 Gene Amplification
by: Yanyang Liu, et al.
Published: (2021-10-01)

Anlotinib can overcome acquired resistance to EGFR‐TKIs via FGFR1 signaling in non‐small cell lung cancer without harboring EGFR T790M mutation
by: Zengzhi Lian, et al.
Published: (2020-07-01)

Efficacy and Safety of Anlotinib Combined with Liposomal Doxorubicin Followed by Anlotinib Maintenance in Metastatic Soft Tissue Sarcomas
by: Liu Z, et al.
Published: (2021-02-01)

Durable efficacy of anlotinib in a patient with advanced thymic squamous cell carcinoma after multiline chemotherapy and apatinib: A case report and literature review
by: Ran Zuo, et al.
Published: (2020-11-01)

Aortic dissection in a patient treated with anlotinib for metastatic lung squamous cell carcinoma
by: Bailing Jiang, et al.
Published: (2020-02-01)

Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer
by: Nanlin Hu, et al.
Published: (2021-08-01)

The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma
by: Yan Song, et al.
Published: (2021-05-01)

Efficacy and safety of anlotinib, a multikinase angiogenesis inhibitor, in combination with epirubicin in preclinical models of soft tissue sarcoma
by: Zhi‐Ming Wang, et al.
Published: (2020-05-01)

Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors
by: Yongkun Sun, et al.
Published: (2016-10-01)

The efficacy and safety of anlotinib treatment for advanced lung cancer
by: Shao L, et al.
Published: (2019-08-01)

Multi-Omics Analysis of Anlotinib in Pancreatic Cancer and Development of an Anlotinib-Related Prognostic Signature
by: Xi Zhang, et al.
Published: (2021-03-01)

Hypertensive Retinopathy Secondary to Anlotinib Treatment
by: Xiaohua Zhang, et al.
Published: (2020-06-01)

Management of anlotinib‐related adverse events in patients with advanced non‐small cell lung cancer: Experiences in ALTER‐0303
by: Xiaoyan Si, et al.
Published: (2019-03-01)

Orbital involvement by NUT midline carcinoma: new presentation and encouraging outcome managed by radiotherapy combined with tyrosine kinase inhibitor: a case report
by: Peiwei Chai, et al.
Published: (2020-01-01)

Efficacy and Safety of Anlotinib for Elderly Patients with Previously Treated Extensive-Stage SCLC and the Prognostic Significance of Common Adverse Reactions
by: Song PF, et al.
Published: (2020-11-01)

Anlotinib Combined With Chemotherapy for Recurrence of Pulmonary Sarcomatoid Cancer Previously Surgically Treated: A Case Report and Literature Review
by: Jing Li, et al.
Published: (2021-05-01)

A Case Report of Advanced Lung Adenocarcinoma Harboring KRAS Mutation  Treated with Anlotinib
by: Yudong SU, et al.
Published: (2018-05-01)

A Case Report of Targeted Therapy with Anlotinib in a Patient with Advanced Breast Metaplastic Carcinoma
by: Zou J, et al.
Published: (2021-08-01)

In vitro studies of H520 cell cycle and apoptosis by anlotinib combined with radiotherapy
by: Lu Guo, et al.
Published: (2021-03-01)

Intervention of Vascular Dysplasia Caused by Different Mechanisms - Anlotinib for Right Lung Squamous Cell Carcinoma Combined with Thromboangiitis Obliterans: A Case Report and Literature Review
by: Huijuan HAO, et al.
Published: (2020-01-01)

A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer
by: Cui Q, et al.
Published: (2021-01-01)

Anlotinib: A Novel Targeted Drug for Bone and Soft Tissue Sarcoma
by: Shenglong Li, et al.
Published: (2021-05-01)

Anlotinib as Exploratory Therapy for Platinum-Resistant Ovarian Cancer: A Retrospective Study on Efficacy and Safety
by: Ni J, et al.
Published: (2020-10-01)

Anlotinib Inhibits PFKFB3-Driven Glycolysis in Myofibroblasts to Reverse Pulmonary Fibrosis
by: Weimou Chen, et al.
Published: (2021-09-01)

Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203)
by: Chun Han, et al.
Published: (2021-07-01)

Case Report: Anlotinib Therapy in a Patient With Recurrent and Metastatic RAIR-DTC Harboring Coexistent TERT Promoter and BRAFV600E Mutations
by: Yanjun Su, et al.
Published: (2021-03-01)

Salvage treatment with anlotinib for advanced non‐small cell lung cancer
by: Di Wu, et al.
Published: (2019-07-01)

Identification of FGFR3-TACC3 gene fusion in metastatic gastric cancer
by: Youjin Kim, et al.
Published: (2017-12-01)

Clinical Efficacy of Anlotinib as Second-line Treatment on Patients with Extensive Small Cell Lung Cancer
by: LIN Jianguang, et al.
Published: (2020-12-01)

Anlotinib Exerts Anti-Cancer Effects on KRAS-Mutated Lung Cancer Cell Through Suppressing the MEK/ERK Pathway
by: Hu H, et al.
Published: (2020-05-01)

Specific Receptor Tyrosine Kinases Promote the Metastatic Phenotype of Osteosarcoma
by: Rettew, Ashley Nicole
Published: (2013)

Dramatic Response of Pulmonary Sarcomatoid Carcinoma to Nivolumab Combined with Anlotinib: A Case Report
by: Caibao Jin, et al.
Published: (2020-06-01)

Short-term Efficacy and Predictive Index of Anlotinib Hydrochloride Capsule on Advanced Non-small Cell Lung Cancer
by: WANG Wei, et al.
Published: (2020-11-01)

Use of anlotinib in intra-abdominal desmoplastic small round cell tumors: a case report and literature review
by: Chen HM, et al.
Published: (2018-12-01)